(RTTNews) – IMV Inc. (IMV) won a notification from the Government of Canada that the company’s DPX-COVID-19 candidate vaccine has reached the clinical and technical thresholds required for the investment. and up to $5. 4 million in investment for continuation of clinical trials.
The IMV vaccine candidate, DPX-COVID-19, is an artificial vaccine aimed at preventing COVID-19 infection. The company will combine its initial Phase 1 and 2 studies into a single trial with the prospective to drive clinical development. The Phase 1/2 trial is expected to be introduced before the end of 2020 and preclinical studies have been conducted since mid-August.
In addition, IMV has established a collaboration with a global production partner. The company said the collaboration aimed to bring two more production sites to India and Europe.